Used in targeted cancer therapy, particularly for hematologic malignancies such as non-Hodgkin lymphoma and chronic lymphocytic leukemia. Binds selectively to CD37, a protein highly expressed on B-cells, triggering cell death through apoptosis and immune-mediated mechanisms like antibody-dependent cellular cytotoxicity (ADCC). Investigated in clinical trials as a monotherapy and in combination with other agents to enhance anti-tumor response. Its humanized design reduces immunogenicity, supporting potential for repeated dosing in treatment regimens.